Video: Biogen Rises Following Novo's Weight-Loss Drug Setback in Alzheimer's Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
- YouTube Launch: The Fly has expanded its stock market reporting by launching a YouTube channel.
- Market Insights: The channel aims to provide insights on market openings and stock movements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 195.610
Low
143.00
Averages
204.45
High
246.00
Current: 195.610
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Biogen for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Biogen Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could significantly impact investor rights.
- Clinical Trial Setback: On May 14, 2026, Biogen announced that the Phase 2 CELIA study results, while described as 'compelling,' failed to meet its primary dose-response endpoint, potentially affecting future research directions.
- Significant Stock Decline: Following the announcement, Biogen's stock price fell by $13.16, or 6.43%, closing at $191.37 per share, reflecting market concerns regarding the company's future prospects.
- Potential Legal Ramifications: The investigation by Pomerantz LLP may lead to a class action lawsuit, which, if established, could have profound implications for Biogen's financial health and reputation, necessitating close monitoring by investors.
See More
Biogen Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Biogen Inc., involving potential misconduct by the company and its executives, which could undermine investor confidence and lead to legal liabilities.
- Clinical Trial Results: On May 14, 2026, Biogen announced topline results from the Phase 2 CELIA study of diranersen (BIIB080) for early Alzheimer's disease, which, despite being described as 'compelling,' failed to meet its primary dose-response endpoint, potentially impacting future research directions.
- Stock Price Decline: Following the announcement, Biogen's stock price fell by $13.16, or 6.43%, closing at $191.37, reflecting market concerns about the company's outlook and investor disappointment over the clinical trial results.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation, has a long history; if the investigation confirms fraud, Biogen could face substantial damages and reputational harm.
See More
Biogen Faces Investigation Over Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Biogen, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Clinical Trial Failure: On May 14, 2026, Biogen revealed that the topline data from its Phase 2 CELIA study did not meet primary endpoints, leading to a significant drop in investor confidence and a 6.4% decline in stock price on the same day.
- Investor Losses: The stock price drop has resulted in direct financial losses for investors, prompting the Schall Law Firm to encourage affected shareholders to participate in the investigation to protect their legal rights.
- Legal Support: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering free consultations to help investors understand their rights and take necessary legal actions.
See More
Biogen Under Investigation for Potential Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Biogen Inc. has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Clinical Trial Results: On May 14, 2026, Biogen announced topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080) for early Alzheimer's disease, which, despite being described as 'compelling,' failed to meet its primary dose-response endpoint.
- Stock Price Reaction: Following the disappointing clinical trial results, Biogen's stock price fell by $13.16, or 6.43%, closing at $191.37 per share, indicating market concerns regarding the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud and corporate misconduct, which could significantly impact Biogen's future legal liabilities.
See More
Latest Wall Street Ratings Overview
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
Revolution Medicines Achieves Strong Phase 3 Clinical Trial Results
- Clinical Trial Success: Revolution Medicines' daraxonrasib achieved an overall survival of 13.2 months in a phase 3 trial for metastatic pancreatic cancer, significantly outperforming the chemotherapy group's 6.7 months, indicating its potential to become the new standard of care and enhancing the company's market position in oncology.
- Massive Market Potential: Analysts predict that daraxonrasib could generate $8.5 billion annually in the metastatic pancreatic cancer market alone, and if approved for additional indications, peak sales could be even higher, highlighting Revolution Medicines' strategic value in addressing high-unmet-need cancer treatments.
- Valuation Risks: With a market cap of $33.6 billion, Revolution Medicines is valued higher than Biogen's $29.3 billion despite lacking market products, suggesting that while the market is optimistic about its future, any clinical or regulatory setbacks could lead to significant stock price declines, increasing investment risks.
- Cautious Investment Advice: Despite Revolution Medicines' impressive clinical progress, analysts recommend that investors wait for a pullback before initiating positions to mitigate risks and gradually build their holdings as the company continues to achieve clinical milestones.
See More
Pomerantz LLP Investigates Biogen for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Biogen Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could significantly impact investor rights.
- Clinical Trial Setback: On May 14, 2026, Biogen announced that the Phase 2 CELIA study results, while described as 'compelling,' failed to meet its primary dose-response endpoint, potentially affecting future research directions.
- Significant Stock Decline: Following the announcement, Biogen's stock price fell by $13.16, or 6.43%, closing at $191.37 per share, reflecting market concerns regarding the company's future prospects.
- Potential Legal Ramifications: The investigation by Pomerantz LLP may lead to a class action lawsuit, which, if established, could have profound implications for Biogen's financial health and reputation, necessitating close monitoring by investors.
See More
Biogen Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Biogen Inc., involving potential misconduct by the company and its executives, which could undermine investor confidence and lead to legal liabilities.
- Clinical Trial Results: On May 14, 2026, Biogen announced topline results from the Phase 2 CELIA study of diranersen (BIIB080) for early Alzheimer's disease, which, despite being described as 'compelling,' failed to meet its primary dose-response endpoint, potentially impacting future research directions.
- Stock Price Decline: Following the announcement, Biogen's stock price fell by $13.16, or 6.43%, closing at $191.37, reflecting market concerns about the company's outlook and investor disappointment over the clinical trial results.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation, has a long history; if the investigation confirms fraud, Biogen could face substantial damages and reputational harm.
See More
Biogen Faces Investigation Over Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Biogen, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Clinical Trial Failure: On May 14, 2026, Biogen revealed that the topline data from its Phase 2 CELIA study did not meet primary endpoints, leading to a significant drop in investor confidence and a 6.4% decline in stock price on the same day.
- Investor Losses: The stock price drop has resulted in direct financial losses for investors, prompting the Schall Law Firm to encourage affected shareholders to participate in the investigation to protect their legal rights.
- Legal Support: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, offering free consultations to help investors understand their rights and take necessary legal actions.
See More
Biogen Under Investigation for Potential Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating whether Biogen Inc. has engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially initiate a class action lawsuit.
- Clinical Trial Results: On May 14, 2026, Biogen announced topline results from the Phase 2 CELIA study evaluating diranersen (BIIB080) for early Alzheimer's disease, which, despite being described as 'compelling,' failed to meet its primary dose-response endpoint.
- Stock Price Reaction: Following the disappointing clinical trial results, Biogen's stock price fell by $13.16, or 6.43%, closing at $191.37 per share, indicating market concerns regarding the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud and corporate misconduct, which could significantly impact Biogen's future legal liabilities.
See More
Latest Wall Street Ratings Overview
- BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
- Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
- Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
- UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
See More
Revolution Medicines Achieves Strong Phase 3 Clinical Trial Results
- Clinical Trial Success: Revolution Medicines' daraxonrasib achieved an overall survival of 13.2 months in a phase 3 trial for metastatic pancreatic cancer, significantly outperforming the chemotherapy group's 6.7 months, indicating its potential to become the new standard of care and enhancing the company's market position in oncology.
- Massive Market Potential: Analysts predict that daraxonrasib could generate $8.5 billion annually in the metastatic pancreatic cancer market alone, and if approved for additional indications, peak sales could be even higher, highlighting Revolution Medicines' strategic value in addressing high-unmet-need cancer treatments.
- Valuation Risks: With a market cap of $33.6 billion, Revolution Medicines is valued higher than Biogen's $29.3 billion despite lacking market products, suggesting that while the market is optimistic about its future, any clinical or regulatory setbacks could lead to significant stock price declines, increasing investment risks.
- Cautious Investment Advice: Despite Revolution Medicines' impressive clinical progress, analysts recommend that investors wait for a pullback before initiating positions to mitigate risks and gradually build their holdings as the company continues to achieve clinical milestones.
See More
